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A novel, sensitive dual-indicator cell 
line for detection and quantification 
of inducible, replication-competent 
latent HIV-1 from reservoir cells
fanny Salasc  1,4, David W. Gludish2,4, isobel Jarvis1, Saikat Boliar2, Mark R. Wills1, 
David G. Russell  2*, Andrew M. L. Lever1,3* & Hoi-ping Mok1*
Understanding the mechanisms involved in HiV infection and latency, and development of a cure, rely 
on the availability of sensitive research tools such as indicator cells, which allow rigorous quantification 
of viral activity. Here we describe the construction and validation of a novel dual-indicator cell line, Sup-
GGR, which offers two different readouts to quantify viral replication. A construct expressing both Gaussia 
luciferase and hrGFP in a Tat- and Rev-dependent manner was engineered into SupT1-CCR5 to create Sup-
GGR cells. This cell line supports the replication of both X4 and R5-tropic HIV as efficiently as its parental 
cell line, SupT1-CCR5, and allows repeated sampling without the need to terminate the culture. Sup-GGR 
demonstrates comparable sensitivity and similar kinetics in virus outgrowth assays (VOA) to SupT1-CCR5 
using clinical samples. However the Gaussia luciferase reporter is significantly less labor-intensive and 
allows earlier detection of reactivated latent viruses compared to the conventional HIV p24 ELISA assay. 
the Sup-GGR cell line constitutes a versatile new tool for HiV research and clinical trials.
Despite significant advances in our understanding of HIV infection and the development of effective antiretrovi-
ral therapy, HIV continues to drive global morbidity and mortality while a cure remains elusive. A major obstacle 
in the HIV cure effort is the persistence of latently infected reservoir cells even after prolonged anti-retroviral 
therapy. An important tool in the detection of this relatively small pool of reservoir cells is an indicator cell line. 
Indicator cells expressing different reporters to identify active viral replication have been invaluable in the detec-
tion and characterization of latently infected cells. Examples include Magi cells, a HeLa based cell line with an 
HIV-LTR driven beta-galactosidase1, and TZM-bl which, in addition to beta galactosidase, also have a luciferase 
reporter2. However, these and other existing systems suffer from their inability to permit repeated sampling of the 
same culture for viral activity, as cells must be lysed to analyze reporter readouts, thus limiting their utility. Here 
we report construction and characterization of a novel dual-indicator cell line, Sup-GGR (Gaussia GFP Reporter) 
that overcomes this limitation. These cells are derived from SupT1-CCR5, a T-lymphoblastic lymphoma cell line 
that stably expresses the HIV-1 receptor CD4, and the co-receptors CCR5 and CXCR4, allowing entry of both X4 
and R5 tropic viruses3. Sup-GGR contains a Tat/Rev dependent expression cassette4 that produces both human-
ized Renilla GFP (hrGFP) and Gaussia luciferase (GLuc) upon HIV infection5.
Uniquely, Gaussia luciferase is secreted into the growth media; as such these supernatants can be harvested 
for reporter readout and replaced with fresh media so that the same culture can be maintained for subsequent 
harvests at different time points.
We validated Sup-GGR cells in virus outgrowth assays (VOA) using clinical samples from HIV infected 
patients. VOA detects inducible, replication-competent HIV in a rigorously defined population of latently 
infected resting CD4 T cells, and is the gold standard in quantifying the replication competent latent reservoir. 
We had previously reported that using SupT1-CCR5 in VOA vastly improved the reproducibility of the assay6. 
Here we made a head to head comparison, and found that the novel Sup-GGR cell line is comparably efficient to 
SupT1-CCR5 in supporting the replication of a range of laboratory and clinical strains of HIV, while maintaining 
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equivalence in virus outgrowth kinetics. Importantly the use of Gaussia luciferase facilitates earlier detection of 
reactivated latent viruses and further streamlines the VOA.
Results
construction of a novel indicator cell line, Sup-GGR. We modified SupT1-CCR5 T-lymphoblastic 
lymphoma cells, known to support the replication of both of X4 and R5 tropic HIV, to express two independent 
indicator genes upon viral infection, Gaussia luciferase (GLuc) and humanized Renilla GFP (hrGFP)6. We used 
a previously published Tat/Rev-dependent vector5, pNL-GGR-RRE (SA), to create the Sup-GGR (Gaussia GFP 
Reporter) cell line. The bicistronic reporter cassette contains GLuc and hrGFP coding sequences separated by 
an internal ribosome entry site (IRES), and is flanked by HIV major splice donor and acceptor sequences. The 
reporter genes are transcribed under the control of the pNL4-3 HIV LTR promoter. The presence of the Rev-
responsive element (RRE) placed downstream of the hrGFP reporter allows the specific transcription and transla-
tion of GLuc and hrGFP genes only in the presence of both Tat and Rev (Fig. 1a). With this reporter cassette, HIV 
infection can be detected by quantification of either the GLuc signal in the culture supernatant or hrGFP fluores-
cence by flow cytometry, microscopy or by plate reader, in addition to the conventional p24 ELISA assay (Fig. 1b).
The SupT1-CCR5 cell line was transduced with the pNL-GGR-RRE (SA) reporter lentiviral vector, expanded 
in culture and cloned by limiting dilution (Fig. 1). More than 200 subclones were obtained and were split and 
replated in replica plates, one replicate of each was infected with stocks of HIV-IRES-mCherry (BaL env), and 
screened for GFP fluorescence by confocal microscopy (data not shown). The HIV-IRES-mCherry vector is 
a full length replication-competent infectious clone based on NL4-3, but encodes the BaL envelope and car-
ries an IRES-mCherry cassette downstream of Nef7. Of the forty-five clones that yielded a GFP-positive signal 
upon infection, three clones were selected by microscopy for infection penetrance and GFP reporter intensity: 
Sup-GGR subclones C6, F1 and H3.
To compare the ability of these 3 subclones to report HIV infection, hrGFP reporter signal intensity was 
assayed by fluorescence microscopy and flow cytometry 6 days post-infection with HIV-IRES-mCherry (BaL 
env), pseudotyped with VSV-G to enhance first round entry (Fig. 1c). All three Sup-GGR clones expressed hrGFP 
Figure 1. Construction of Sup-GGR cells. (a) Schematic of SupT1-GGR5 derivation. SupT1-CCR5 cells 
were transduced with the lentiviral reporter vector pNL-GGR-RRE (SA), and cloned by limiting dilution. The 
bicistronic expression cassette contains two reporter genes under the control of a Tat-dependent HIV LTR 
promoter. The incorporation of the HIV major splice donor and acceptor sites and a Rev Response Element 
also renders reporter expression Rev dependent. (b) Compared to the parental SupT1-CCR5 (top panel), Sup-
GGR offers two additional readouts of HIV activity – GLuc and hrGFP expression. (c) Individual Sup-GGR 
subclones C6, F1 and H3 were infected with VSV/G-HIV-IRES-mCherry replication competent HIV, and the 
GGR reporter signal was assayed by fluorescence microscopy (top row) and flow cytometry (bottom) at six days 
post-infection. Clone F1 gave the highest proportion of dual positive cells (top center quadrant) with trivial 
background hrGFP expression and was chosen for further characterization. (d) Titer (TCID50/mL) for a stock 
of non-pseudotyped HIV-IRES-mCherry (BaL env) was calculated by serial dilution in Sup-GGR (orange, 
TCID50Sup = 0.72 × 104/mL) and the widely employed cell reagent, TZM-bl (grey, TCID50TZM = 1.16 × 104/mL), 
showing comparable susceptibility to HIV infection.
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upon HIV infection but with variability between the clones. A higher proportion of hrGFP+/mCherry+ cells was 
seen in Sup-GGR-F1 compared to Sup-GGR-C6 and Sup-GGR-H3. The same profile was observed by flow cytom-
etry with 19.6% of cells positive for both GFP and mCherry for Sup-GGR-F1 compared to 12.7% for Sup-GGR-C6 
and 11.8% for Sup-GGR-H3. A proportion of cells were infected with mCherry virus but did not express hrGFP 
(30.8% for Sup-GGR-F1, 22.1% for Sup-GGR-C6 and 23% for Sup-GGR-H3); these mCherry(low) cells presuma-
bly correspond to early infection prior to induction of the hrGFP reporter. Importantly, double-positive hrGFP+/
mCherry+ cells were 1.5–2 logs higher in mCherry fluorescence than single positive hrGFP-/mCherry(low) 
cells. Additionally a very small proportion of cells expressed hrGFP in the absence of HIV infection (0.75% 
for Sup-GGR-F1, 0.84% for Sup-GGR-C6 and 1.50% for Sup-GGR-H3). Based on these results, the subclone 
Sup-GGR-F1 was selected for subsequent experiments.
To characterize the Sup-GGR-F1 clone further, we infected it with serial dilutions of HIV-IRES-mCherry 
(BaL env) stocks, and calculated the 50% tissue culture infective dose (TCID50/mL) compared to TZM-bl cells 
(Fig. 1d). Both cell types demonstrated comparable sensitivity to HIV infection with a TCID50 of 0.72 × 104/
mL and 1.16 × 104/mL for SupGGR-F1 and TZM-bl, respectively. The Sup-GGR-F1 clone was thus renamed 
Sup-GGR and selected for additional validation.
Sensitivity of Sup-GGR cell line to infection by replication-competent laboratory HiV 
strains. We tested the ability of Sup-GGR cells to capture and sustain replication of X4 and R5 tropic HIV 
viruses in a cell-to-cell transfer milieu compared to the parental SupT1-CCR5 line. SupT1-CCR5 cells were 
infected with X4 tropic viruses, NL4-3 and LAI, or R5 tropic viruses, BaL and JR-CSF. HIV infected SupT1-CCR5 
cells were used as donor cells and then co-cultured at serial fivefold dilutions with either uninfected SupT1-CCR5 
or uninfected Sup-GGR. Each dilution was assayed in 10 replicates and cytopathic effects (CPE) were checked 
every day for 21 days. The percentage of infected cells was determined by limiting dilution statistics8. Figure 2a 
shows the results of three independent experiments. The percentage of infected cells in each experiment was var-
iable, but crucially the results obtained from Sup-GGR were comparable to that from SupT1-CCR5 irrespective 
of the input donor cell number for three (NL4-3, BaL and JR-CSF) out of four strains of viruses. This is also illus-
trated in Fig. 2b showing the ratio of the percentage of infected cells detected by Sup-GGR over that detected by 
SupT1-CCR5 for each virus strain. A ratio >1 would indicate Sup-GGR was better able to support the replication 
of the strain of virus tested compared with SupT1-CCR5, and a ratio <1 would indicate Sup-GRR was less able to 
support the replication of this strain of virus. As the ratios for NL4-3, BaL and JR-CSF are around 1 (1.37, 0.73 and 
0.98 for NL4-3, BaL and JR-CSF, respectively), Sup-GGR are demonstrably as efficient as Sup-CCR5 in supporting 
the replication of these strains of virus (Fig. 2b). For LAI, the ratio is 3.57 but the 95% confidence limits of the 
ratio is between 0.62 and 6.53 and is not statistically significantly greater than 1 (Fig. 2a,b). Representative kinetics 
from three replicate experiments are shown in Fig. 2c. The Sup-GGR cells exhibit similar kinetics of infection 
compared with SupT1-CCR5 for all X4 and R5 strains tested. Thus Sup-GGR cells support HIV replication of 
both X4 and R5-tropic laboratory strains at least as efficiently as SupT1-CCR5 cells line and with similar kinetics.
Efficient detection of reactivated latent viruses from CD4+ T cells isolated from HIV-1 infected 
individuals by Sup-GGR cell line. Virus outgrowth assay currently provides the most definitive minimal 
estimate of the size of the latent reservoir9. The VOA involves limiting dilution of patient-derived resting CD4+ 
T cells, followed by reactivation of latent viruses in vitro. Reactivated latent viruses are allowed to replicate in 
reporter cells both to demonstrate that the virus is replication competent and to allow signals to amplify for 
accurate quantitation. The culture is sampled at different time-points for evidence of viral activity. We previously 
reported that using SupT1-CCR5 as reporter cells to facilitate the replication of reactivated latent viruses in VOA 
improves the reproducibility of the assay compared to using uninfected donor-derived T-lymphocytes6. Here we 
assessed the capacity of Sup-GGR cells to detect reactivated latent viruses from primary resting CD4+ T cells 
from HIV infected patients. Briefly, resting CD4+ T cells were purified from patients and were subjected to limit-
ing dilution such that approximately a third to a half of all wells are predicted to contain an inducible latent virus. 
Resting cells were activated with phytohaemagglutinin-L (PHA-L) and irradiated allogeneic PBMCs in the pres-
ence of IL-2, and co-cultured with either Sup-GGR or SupT1-CCR5. In addition wells containing Sup-GGR with-
out resting CD4+ T cells were used as a negative control for baseline GLuc and hrGFP expression. Samples were 
harvested at regular intervals for p24 ELISA, luciferase and flow cytometry analyses. Supplementary Figure S1 
illustrates the threshold applied for negative vs positive wells for flow cytometry and GLuc detection.
We first compared the percentage of positive wells detected by p24 ELISA in either Sup-GGR or SupT1-CCR5 
co-culture wells at 33 days post-activation. The analysis was performed on five HIV+ patients (Supplementary 
Table S1). As shown in Fig. 3a, within each patient the proportion of positive wells co-cultured with SupT1-CCR5 
and Sup-GGR were similar (50% vs 58%, 25% vs 8.3%, 14.3% vs 14.3%, 50% vs 62.5% and 12.5% vs 0 for patient 
#1 to #5, respectively). Furthermore there is no significant difference between Sup-GGR and SupT1-CCR5 
(p = 0.75, Wilcoxon matched-pairs signed rank test, two tailed test). Table 1 summarizes the number of positive 
wells obtained for each patient in either in Sup-GGR and SupT1-CCR5. Similarly, the kinetics of virus outgrowth, 
whilst variable between patients, were similar in Sup-GGR and SupT1-CCR5 for each patient (Fig. 3b). Overall 
these experiments showed that the Sup-GGR cell line is at least as efficient as SupT1-CCR5 in supporting replica-
tion of HIV reactivated ex vivo from primary CD4+ T cells.
Sup-GGR cells express GLuc and hrGFP when infected with HIV. We analysed both readouts in addition to 
p24 ELISA during VOA and compared their efficiency in detecting reactivated viruses. Figure 4a, showing the 
cumulative total number of positive wells from all five patients over the course of VOA, illustrates the kinetics 
of virus outgrowth as determined by the three readouts. Table 2 shows the day at which a well becomes positive 
with various modes of detection. The table contains data from 17 positive wells derived from 5 patients. In 11/17 
samples GLuc gave an earlier detection, in 4/17 they were equivalent, and only in 2/17 did conventional p24 
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Figure 2. Sup-GGR can readily detect X4-tropic viruses (NL4-3 and LAI) or R5-tropic viruses (BaL and 
JR.CSF). (a) SupT1-CCR5 cells were infected with various strains of viruses (NL4-3, LAI, BaL or JR-CSF) and 
serial fivefold dilution (starting from 625 cells per well) of infected cells were co-cultured with uninfected 
Sup-GGR (circle) or SupT1-CCR5 (triangle) in 96 well plates, with 10 wells/dilution. Cytopathic effects were 
assessed every day for 21 days and the percentage of infected cells in the stock was calculated based on limiting 
dilution statistics. Three independent experiments are represented, each experiment is depicted by a different 
color (blue, grey or orange). (b) Ratio of the percentage of infected cells in the stock detected by Sup-GGR over 
that detected by SupT1-CCR5 for each strain of virus, using data from (a). Three independent experiments 
were performed. Error bars indicates standard deviation. The ratios are around 1 for all four strains of viruses 
indicating that SupGGR is at least as efficient as SupT1-CCR5 in supporting HIV replication. (c) Percentage 
of infected cells as determined for Sup-GGR (blue) or SupT1-CCR5 (pink) at different days post-infection 
demonstrating the kinetics of infection. One representative experiment from 3 replicates is presented.
5Scientific RepoRtS |         (2019) 9:19325  | https://doi.org/10.1038/s41598-019-55596-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
ELISA yield an earlier detection. The average time to detection is shorter with GLuc at 17.8 days (median 18 days) 
post-activation, compared with 21.5 days (median 18 days) with p24 ELISA and 20.8 days (median 19 days) with 
flow cytometry for hrGFP (GLuc vs p24 ELISA, p = 0.03; GLuc vs flow cytometry, p = 0.001, two tailed ‘t’ test). 
This translates to a significant reduction in time to culture-positivity requirement for VOA (Table 3). In the five 
patients tested, to capture all the positive wells, on average 22.8 days (median 22 days) would be required with 
GLuc as readout, compared to 27.6 days (median 27 days) for flow cytometry and 31 days (median 33 days) for 
p24 ELISA (GLuc vs p24 ELISA, p = 0.04; GLuc vs hrGFP, p = 0.03, two tailed ‘t’ test). In addition to detecting 
positive wells sooner, we unexpectedly observed that in two wells (one from patient #3 and one from patient #5), 
viral activity could be detected by GLuc but not by p24 ELISA. We could observe CPE in these wells and one of 
them was also positive by flow cytometry (patient #3) (Fig. 4b).
Altogether these results showed that the new indicator cell line, Sup-GGR, is at least as efficient as 
SupT1-CCR5 in supporting replication of HIV reactivated ex vivo from primary resting CD4+ T cells. In addi-
tion, Gaussia luciferase assay facilitates earlier detection of viral outgrowth. As the detection of GLuc secreted 
Figure 3. SupT1-GGR5 cells are as sensitive as SupT1-CCR5 in co-culture assay. Highly purified resting CD4+ 
T cells were obtained from whole blood of five HIV+ patients. These cells were activated with PHA-L and 
allogeneic irradiated PBMC, seeded at 4–8 × 105 cells per well (depending on donor), and co-cultured with 
either SupT1-CCR5 or Sup-GGR. Samples were harvested regularly for p24 ELISA, GLuc detection and flow 
cytometry analyses. (a) Percentage of positive wells from five different patients when stimulated resting CD4+ 
T cells were co-cultured with each cell type, using p24 ELISA as readout. Each color represents resting CD4+ 
T cells isolated from one patient co-cultured with either Sup-GGR (circle) or SupT1-CCR5 (triangle). The total 
number of wells seeded for each patient is shown in Table 1. There is no significant difference between Sup-GGR 
and SupT1-CCR5 (p = 0.75, Wilcoxon matched-pairs signed rank test, two tailed test). (b) Virus outgrowth 
kinetics using Sup-GGR cell line (blue) or SupT1-CCR5 (pink). Results represent ex vivo co-culture from five 
different patients (#1 to #5).
Sup-GGR SupT1-CCR5
#1 6/12 7/12
#2 3/12 1/12
#3 1/7* 1/7
#4 4/8 5/8
#5 1/8* 0/8
Table 1. Number of positive wells detected in Sup-GGR vs SupT1-CCR in VOA. The number of wells used 
for each patient is dependent on the number of resting cells available from each venesection. Asterisks identify 
patients for which one additional well was found positive with luciferase in Sup-GGR but not with ELISA. There 
is no significant difference between Sup-GGR and SupT1-CCR5 (p = 0.75, Wilcoxon matched-pairs signed rank 
test, two tailed test).
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Figure 4. Luciferase facilitates earlier detection of reactivated latent viruses compared to p24 ELISA and flow 
cytometry. (a) Total number of positive wells aggregated from all five patients, as determined by p24 ELISA 
(blue), luciferase (orange) and flow cytometry (grey) at different days of co-culture. (b) Virus outgrowth kinetics 
as determined by p24 ELISA (blue), luciferase (orange) and flow cytometry (grey) for each patient (#1 to #5).
Well GLuc p24 hrGFP
#1
1 18 13 18
4 22 33 27
5 18 13 18
7 22 27 27
11 22 22 27
12 18 18 18
#2
2 11 14 11
3 14 18 14
10 25 32 35*
#3
1 12 36* 19
2 19 22 22
#4
1 12 15 15
2 12 15 15
4 15 15 19
6 8 12 15
#5
4 21 21 21
6 33 39* 33
average 17.8 21.5 20.8
median 18 18 19
Table 2. Time to detection for the positive wells (days post activation) by the mode of readout for all five 
patients in VOA (#1 to #5). Asterisks indicate the last censored day rather than day when the readout was 
positive. The average time to detection is shorter with Gaussia luciferase compared with both p24 ELISA and 
flow cytometry (GLuc vs p24 ELISA, p = 0.03; GLuc vs flow cytometry, p = 0.001, two tailed ‘t’ test).
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by Sup-GGR can be achieved without lysis of the cells, the indicator cell is an excellent tool to detect reactivated 
virus in a VOA setting.
Discussion
Indicator cell lines that can detect the presence of virus are essential tools in virological research. Here we describe 
a new dual-indicator cell line, Sup-GGR, that expresses GLuc and hrGFP upon HIV infection. Systems such as 
HIV latency cell lines10,11, and cells containing bicistronic promoter/reporter constructs12–18 have been previously 
described and are valuable tools to study HIV. These can allow identification and/or isolation of cells containing 
an integrated provirus12, study of LTR function16, and screening for antiviral activity13,15. Unlike prior systems 
however, our dual-indicator cell line is a reporter system primarily designed to detect the presence of replica-
tion competent HIV reactivated from primary CD4+ T cells. Existing indicator cell lines for HIV-12 must be 
lysed to allow reporter gene expression readout, and thus cannot be used for repeat sampling of an individual 
culture. Importantly, GLuc detection allows extended follow-up of HIV replication because it is secreted into the 
supernatant obviating cell lysis. Sup-GGR cells support the replication of both X4- and R5-tropic HIV, at least as 
efficiently as the parental SupT1-CCR5 line. We did not observe any discrepancy in the detection of HIV with this 
reporter with the five clinical isolates compared to conventional p24 assay. Here we have not formally tested the 
reporter on all the subtypes of HIV. The reporter genes rely on the activity of viral Tat and Rev, and genetic and 
functional variations in Tat19–21, and Rev22 between different strains of viruses has been described. Similar to the 
current HIV-1 LTR-based reporter cells available in the field, there is thus a theoretical concern that the reporter 
cassette may report infection with some viral strains at a lower efficiency, and indeed may be incompatible with 
others. Our ongoing pursuits employ Sup-GGR cells to study the kinetics and biology of full-length HIV isolates, 
including uncloned swarms from patient material; such experiments are traditionally pursued using cloned enve-
lopes in reporter lentiviral vectors and can only study envelope-mediated viral entry.
We demonstrated the utility of Sup-GGR in detecting reactivated latent viruses. Sup-GGR has equivalent 
sensitivity when deployed in VOA, compared with the parental SupT1-CCR5 cell line. Virus outgrowth kinetics 
are similar in a head to head comparison with SupT1-CCR5, using p24 ELISA as readout. We have also com-
pared the three readouts of viral activity - supernatant p24, supernatant Gaussia luciferase and hrGFP, available 
with Sup-GGR in VOA. In this context, we did not find flow cytometry for hrGFP expression offered significant 
advantages over supernatant p24 ELISA. HIV infection is lethal to Sup-GGR, thus limiting the window during 
which infected cells are both viable and hrGFP positive to be included in analysis. In addition, the VOA protocol 
requires Sup-GGR to be co-cultured with irradiated allogeneic PBMC and ex vivo CD4+ T cells. There is thus a 
large background of cells that will not express GFP, limiting the sensitivity of this readout.
Interestingly we observed two wells (patient #3, well 1, patient #5, well 6) where Tat/Rev reporter driven read-
outs (Gaussia luciferase) were positive with Sup-GGR, and supernatant p24 ELISAs were negative. This may rep-
resent very early stages of viral replication prior to sufficient accumulation of budded viruses in the supernatant 
to allow detection by p24 ELISA assay. Importantly, tools such as Sup-GGR afford the opportunity to study such 
events that may be missed using standard platforms for viral outgrowth quantitation.
One key improvement with Sup-GGR is the significant advantages that secreted Gaussia luciferase provide 
over conventional p24 ELISA both in terms of detection and labor. Whilst there is patient-to-patient variation in 
the latent load (which is expected), in most cases positive wells can be identified by Gaussia luciferase significantly 
earlier than by p24. This is true irrespective of the manner of analysis: by the proportion of positive wells detected 
by various methods, by the average time to positivity, and most importantly for use in VOA, by the overall time 
required to capture all positive wells. For this study we prolonged the tissue culture period in VOA to 33 days 
instead of the usual 23 days. We found that just under one third of all wells which eventually turned positive did 
so late and would have been scored as negative with the standard VOA protocol where viruses were cultured for 
three weeks and ELISA was used as the readout. Thus premature termination of VOA may also lead to an under-
estimation of the size of the latent reservoir. However, more than half of those wells would be scored as positive 
if luciferase were used as the readout, without the need to prolong the culture period. In addition, using Gaussia 
luciferase as readout also offered significant time savings with respect to readout. In our hands Gaussia luciferase 
could be read in under half an hour, whilst an ELISA requires nearly 5 hours of laboratory time. Such savings can 
improve the scalability of VOA.
In summary we report here the construction and validation of a new dual-indicator cell line, Sup-GGR, to 
assess HIV replication. Sup-GGR expresses two readout signals when infected with HIV, Gaussia Luciferase 
GLuc p24 hrGFP
#1 22 33 27
#2 25 32 35*
#3 19 36* 26
#4 15 15 19
#5 33 39* 33
average 22.8 31 27.6
median 22 33 27
Table 3. Times for all wells to turn positive in VOA for each patient by the mode of detection. Asterisks indicate 
last censored date when a well tested positive by another method remains negative with the indicated mode of 
detection (GLuc vs p24 ELISA, p = 0.04; GLuc vs hrGFP, p = 0.03, two tailed ‘t’ test).
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which is secreted into the supernatant and intracellular hrGFP. Unlike other indicator cells, Sup-GGR permits 
repeated samplings without terminating the culture. Sup-GGR can potentially be used in a wide range of applica-
tions, such as in extended experiments like VOA to track HIV replication.
Materials and Methods
patient cohort. The participants gave written informed consent and this study was approved by the National 
Health Services (NHS) Health Research Authority (UK) under REC reference 12/SC/0679. All experimental 
procedures were approved by the institutional review boards of the University of Cambridge and were performed 
in accordance with the relevant guidelines. Clinical characteristics of the patients are described in Supplementary 
Table 1.
cells. TZM-bl cells were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. SupT1-CCR5 cells were a generous gift 
from Dr. James Hoxie, University of Pennsylvania. Affinofile-GGR cells were graciously provided by Dr. Benhur 
Lee, Mount Sinai School of Medicine. 293FT cells were purchased from Invitrogen.
Viruses. HIV clones JR-CSF, BaL, NL4-3, and LAI were acquired through the NIH AIDS Reagent Program. 
HIV-IRES-GFP (BaL env) was a gift of Drs. Thorsten Mempel, MGH, and Thomas Murooka, University of 
Manitoba. HIV-IRES-mCherry (BaL env) was generated by cloning the mCherry cDNA into HIV-nef-IRES-GFP, 
using PCR amplification from pCAAGS-mCherry (a kind gift of Dr. Natasza Kurpios, Cornell University) and 
cloning a 1.7 kb MluI-IRES-mCherry-LTR-XbaI cassette into digested pNL43-IRES-GFP(BaL env).
cell culture. SupT1-CCR5 cells and Sup-GGR were maintained in RPMI 1640 with L-glutamine supple-
mented with 10% Fetal Bovine Serum and 1% penicillin/streptomycin. SupT1-CCR5 and Sup-GGR cells were 
split 1:10 twice weekly. Adherent cell lines TZM-bl, Affinofile-GGR, and 293-FT were maintained in DMEM with 
L-glutamine supplemented with 10% Fetal Bovine Serum, 1X sodium pyruvate, 1X HEPES and 1% penicillin/
streptomycin. Cells were split 1:10 every three days.
fluorescence microscopy. Fluorescent signal from reporter cells or infectious HIV clones encoding fluoro-
phores were imaged live under BSL3 containment on a Leica SP-5 laser scanning confocal microscope using 
either a universal plate holder for glass-bottom or chamber glass culture formats, or the H201–MEC–LG–MW 
holder (OkoLabs) for optical bottom 96-well plate culture assays. Z-stacks were projected, and channels merged 
and contrasted in Leica Application Suite or Adobe Photoshop.
establishment of an indicator cell line carrying the Gaussia luciferase and Gfp sig-
nal. Affinofile-GGR cells were transfected with pCMV-dR8.2-dvpr and pLP-VSV/G to package the GGR pro-
virus integrated in these cells. At 48-hours post-transfection, harvested supernatant was used to spinoculate target 
SupT1-CCR5 cells at 1000 × g for two hours at room temperature in the presence of 10 µg/mL DEAE-dextran. 
Infected cells were then resuspended in fresh medium, expanded for one week in culture, and plated at limiting 
dilution (~0.5 cells/well) in 96-well round bottom dishes. Plates were spun at 2000 × g for 30 minutes, and single 
cells verified by phase contrast microscopy. Cell clones were expanded for two weeks, then split among four rep-
licate plates and further expanded for testing of reporter activity.
Reporter screening in Sup-GGR cell clones. Subclones of Sup-GGR were screened for reporter activity 
by infection with VSV-G pseudotyped or wild type full length HIV-IRES-mCherry (BaL env) HIV stocks. Wells 
were live imaged by confocal microscopy, and reporter fluorescence was quantified either live on a BioRad S3e cell 
sorter or following fixation (BD Cytofix/Cytoperm) on a BD LSRII flow cytometer.
Infection of SupT1-CCR5 and Sup-GGR with laboratory virus strains. SupT1-CCR5 were infected 
with different strains of viruses: NL4-3, LAI, BaL or JR-CSF. Cells were carefully washed three times to remove 
excess virions. Serial fivefold dilution of these stocks of infected cells were co-cultured with 50000 cells/well of 
either uninfected Sup-GGR or SupT1-CCR5 in 96 well plates with ten wells for each dilution. Wells were checked 
for cytopathic effects every day for 21 days and the percentage of infected cells in the stock was calculated based 
on limiting dilution statistics8. Three independent experiments were performed.
50% tissue culture infective dose (TCID50). Stocks of HIV-IRES-mCherry were titered on TZM-bl and 
Sup-GGR cells. To 2,500 target cells in 96-well format were added 5 μL of five-fold serially-diluted HIV stock, 
in the absence of DEAE-dextran. At 72 hours post-infection, HIV-mCherry positive wells were scored and the 
fraction of positive wells used to discern the TCID50/mL for each viral stock according to the Reed-Muench 
method23.
Quantitative viral outgrowth assay. VOA was performed as previously described with modifications6. 
Briefly, PBMCs were isolated from whole blood by density gradient centrifugation using Lymphoprep (Alere 
Technologies AS, Oslo, Norway). Resting (CD25−, CD69−, HLA-DR−) CD4+ T cells were negatively selected 
using a custom antibody cocktail (StemCell Technologies) and cultured with 20 nM efavirenz and 100 nM ral-
tegravir for 1 to 2 days to allow for the degradation of unintegrated viral DNA. On ‘day 1’ of the assay, cells were 
washed thoroughly to remove antiretroviral drugs, stimulated with 10-fold excess of irradiated allogeneic PBMCs 
and 2 μg/ml PHA-L in RPMI medium containing 10 U/ml IL-2, and seeded at 4–8 × 105 resting cells per well in 
9Scientific RepoRtS |         (2019) 9:19325  | https://doi.org/10.1038/s41598-019-55596-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
12 well plates. 24 hours after stimulation, media containing PHA-L was removed and replaced with 3 ml of fresh 
media containing IL-2 and SupT1-CCR5 or Sup-GGR cells at 5 × 105 cells per well. Negative control wells con-
taining Sup-GGR without resting CD4+ T cells were included to account for background luciferase and hrPGF 
expressions in subsequent analyses. After the first week, half of the media and cells were harvested twice weekly 
and replaced with fresh media with IL-2. The culture was maintained for a minimum of 33 days. Supernatant 
was inactivated in 0.1% Empigen at 56 °C for 30 minutes and analysed for HIV-1 p24 production by ELISA and 
Gaussia luciferase expression (Pierce Gaussia Luciferase Flash Assay Kit, Thermo Scientific). Cell were washed 
twice, fixed in 300 µL of 4% paraformaldehyde and GFP+ cells were quantified by flow cytometry (BD Accuri 
C6). Supplementary Figure S1 illustrates the threshold applied for negative vs positive wells for flow cytometry 
and GLuc detection.
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